Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...
DexCom, Inc. DXCM announced that its latest G7 continuous glucose monitoring (CGM) system can now connect with Tandem Diabetes Care's t:slim X2 insulin pump featuring Control-IQ technology. This ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has granted clearance to a ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...
Zacks Investment Research on MSN
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...
It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset, but management are optimistic about rebuilding BME sales channel. DexCom's newest G7 CGM competes closely ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback